首頁 > 市場調查報告書 > 製藥

以基因為基之藥物開發

市場調查報告書

商品編碼

1729317

日本藥物基因組學市場報告（按技術、應用、最終用戶和地區）2025-2033

Japan Pharmacogenomics Market Report by Technology, Application, End User, and Region 2025-2033

出版日期: 2025年05月01日 | 出版商:

IMARC | 英文 118 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024 年，日本藥物基因體學市場規模達 3.784 億美元。展望未來， IMARC Group預計到 2033 年該市場規模將達到 6.711 億美元，2025-2033 年期間的成長率 (CAGR) 為 6.08%。不斷擴大的醫療保健基礎設施、日益成長的老齡化人口、主要參與者持續的研究和開發 (R&D) 活動以及政府機構和醫療保健組織不斷增加的教育舉措是推動市場發展的一些關鍵因素。

藥物基因體學是研究基因如何影響個體對藥物的反應的學科。這門科學學科結合了藥理學（藥物科學）和基因組學（研究基因及其功能）的元素。藥物基因體學的主要目的是最佳化藥物治療，最大限度地提高療效，同時最大限度地減少副作用。藥物基因組學使得醫療方法更加個人化。它可以根據個人的基因組成來制定個人化的醫療治療。這意味著可以針對每個人設計最適合的治療方法，從而提高療效。個人化治療可以減輕醫療保健系統的財務負擔。開藥過程中的嘗試和錯誤減少意味著患者可以更快地獲得有效治療，從而減少住院時間並降低整體醫療成本。藥物基因組學還可以使製藥公司受益，因為它可以確定新的藥物靶點，並幫助開發更有效、更安全的藥物，從而更快地獲得監管部門的批准。

日本藥物基因體學市場趨勢：

日本擁有強大的醫療保健基礎設施，以尖端技術和先進的研究設施為特點，正在推動日本市場的發展。日本在技術和醫學領域的領先地位為藥物基因組學的發展提供了有利的環境，並在研發方面投入了大量資金。此外，政府對基因組學研究的大力支持也為市場提供了支撐。監管政策和資金旨在鼓勵個人化醫療（包括藥物基因組學）的創新。日本政府已推出多項舉措，加速基因組學研究及其在醫療中的應用，從而為藥物基因組學市場蓬勃發展創造良好的生態系統。日本人口老化也在擴大市場方面發揮關鍵作用。老年人更有可能有複雜的醫療保健需求和多種藥物，使他們成為個人化治療計劃的理想人選。藥物基因組學可以為這一人群提供有效且安全的最佳化藥物療法，減少藥物不良反應，而藥物不良反應是老年人住院的主要原因。此外，日本某些疾病的發生率相對較高，可以從藥物基因組學應用中受益，包括各種類型的癌症和心血管疾病。針對這些常見疾病制定個人化治療方案的能力可以改善治療效果並降低醫療成本，從而使藥物基因組學成為醫療保健提供者和患者都青睞的選擇。此外，大眾對個人化醫療益處的認知不斷提高，也推動了市場的發展。此外，政府機構和醫療保健組織的教育措施也有助於人們更好地了解藥物基因組學的優勢，從而鼓勵更多人選擇此類測試和治療。

日本藥物基因組學市場細分：

技術洞察：

聚合酶鍊式反應
微陣列
DNA定序
質譜法
電泳
其他

應用程式洞察：

腫瘤學
傳染病
心血管疾病
神經系統疾病
精神病學
疼痛管理
其他

最終用戶洞察：

醫院和診所
學術和研究機構

競爭格局：

市場研究報告也對市場競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀表板和公司評估象限等競爭分析。此外，也提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

日本藥物基因組學市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本藥物基因體學市場有何影響？
日本藥物基因體學市場根據技術如何分類？
日本藥物基因體學市場根據應用如何分類？
根據最終用戶，日本藥物基因組學市場是如何分類的？
日本藥物基因體學市場的價值鏈分為哪些階段？
日本藥物基因體學的主要促進因素和挑戰是什麼？
日本藥物基因體學市場的結構是怎麼樣的？主要參與者是誰？
日本藥物基因體學市場的競爭程度如何？

本報告回答的關鍵問題：

日本藥物基因組學市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本藥物基因體學市場有何影響？
日本藥物基因體學市場根據技術如何分類？
日本藥物基因體學市場根據應用如何分類？
根據最終用戶，日本藥物基因組學市場是如何分類的？
日本藥物基因體學市場的價值鏈分為哪些階段？
日本藥物基因體學的主要促進因素和挑戰是什麼？
日本藥物基因體學市場的結構是怎麼樣的？主要參與者是誰？
日本藥物基因體學市場的競爭程度如何？

Japan pharmacogenomics market size reached USD 378.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 671.1 Million by 2033, exhibiting a growth rate (CAGR) of 6.08% during 2025-2033. The expanding healthcare infrastructure, increasing aging population, continual research, and development (R&D) activities by leading players, and rising educational initiatives by government bodies and healthcare organizations represent some of the key factors driving the market.

Pharmacogenomics is the study of how genes influence an individual's response to medications. This scientific discipline combines elements of pharmacology, which is the science of drugs, and genomics, which is the study of genes and their functions. The primary aim of pharmacogenomics is to optimize drug therapy, maximizing effectiveness while minimizing adverse effects. Pharmacogenomics allows for a more personalized approach to medicine. It allows for tailored medical therapy based on an individual's genetic makeup. This means that treatments can be specifically designed to work best for each person, enhancing effectiveness. Personalized treatment can reduce the financial burden on the healthcare system. Fewer trials and errors in prescribing medication mean that patients can potentially reach an effective treatment faster, reducing hospital stays and lowering overall healthcare costs. Pharmacogenomics can also benefit pharmaceutical companies by identifying new drug targets and assisting in the development of medication that is more effective and safer, which can lead to faster regulatory approval.

Japan Pharmacogenomics Market Trends:

The country's robust healthcare infrastructure, characterized by cutting-edge technology and advanced research facilities, is driving the market in Japan. Japan's reputation as a leader in the field of technology and medicine facilitates a supportive environment for the growth of pharmacogenomics, with significant investments in research and development. Moreover, the strong government support for genomics research is supporting the market. Regulatory policies and funding are geared towards encouraging innovations in personalized medicine, including pharmacogenomics. The Japanese government has launched several initiatives to accelerate research in genomics and its application in medical treatments, thereby creating a favorable ecosystem for the pharmacogenomics market to flourish. The aging population in Japan also plays a critical role in augmenting the market. Older individuals are more likely to have complex healthcare needs and multiple medications, making them ideal candidates for personalized treatment plans. Pharmacogenomics can offer optimized drug therapies that are both effective and safe for this demographic, reducing adverse drug reactions, which are a leading cause of hospitalization among the elderly. In addition, Japan has a relatively high incidence of certain diseases that can benefit from pharmacogenomic applications, including various types of cancer and cardiovascular disorders. The ability to tailor treatments for these prevalent conditions can improve outcomes and reduce healthcare costs, making pharmacogenomics an attractive option for both healthcare providers and patients. Furthermore, the market is fueled by increasing public awareness about the benefits of personalized medicine. Besides, educational initiatives by government bodies and healthcare organizations have also contributed to a greater understanding of the advantages of pharmacogenomics, thus encouraging more people to opt for such tests and treatments.

Japan Pharmacogenomics Market Segmentation:

Technology Insights:

Polymerase Chain Reaction
Microarray
DNA Sequencing
Mass Spectrometry
Electrophoresis
Others

Application Insights:

Oncology
Infectious Diseases
Cardiovascular Diseases
Neurological Diseases
Psychiatry
Pain Management
Others

End User Insights:

Hospitals and Clinics
Academic and Research Institutes

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan pharmacogenomics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan pharmacogenomics market?
What is the breakup of the Japan pharmacogenomics market on the basis of technology?
What is the breakup of the Japan pharmacogenomics market on the basis of application?
What is the breakup of the Japan pharmacogenomics market on the basis of end user?
What are the various stages in the value chain of the Japan pharmacogenomics market?
What are the key driving factors and challenges in the Japan pharmacogenomics?
What is the structure of the Japan pharmacogenomics market and who are the key players?
What is the degree of competition in the Japan pharmacogenomics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Pharmacogenomics Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Pharmacogenomics Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Pharmacogenomics Market - Breakup by Technology

6.1 Polymerase Chain Reaction
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Microarray
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 DNA Sequencing
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Mass Spectrometry
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2019-2024)
- 6.4.3 Market Forecast (2025-2033)
6.5 Electrophoresis
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2019-2024)
- 6.5.3 Market Forecast (2025-2033)
6.6 Others
- 6.6.1 Historical and Current Market Trends (2019-2024)
- 6.6.2 Market Forecast (2025-2033)

7 Japan Pharmacogenomics Market - Breakup by Application

7.1 Oncology
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Infectious Diseases
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Cardiovascular Diseases
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
7.4 Neurological Diseases
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
7.5 Psychiatry
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2019-2024)
- 7.5.3 Market Forecast (2025-2033)
7.6 Pain Management
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2019-2024)
- 7.6.3 Market Forecast (2025-2033)
7.7 Others
- 7.7.1 Historical and Current Market Trends (2019-2024)
- 7.7.2 Market Forecast (2025-2033)

8 Japan Pharmacogenomics Market - Breakup by End User

8.1 Hospitals and Clinics
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Academic and Research Institutes
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)

9 Japan Pharmacogenomics Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Product Portfolio
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Product Portfolio
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Product Portfolio
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Product Portfolio
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Product Portfolio
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Pharmacogenomics Market - Industry Analysis

11.1 Drivers, Restraints and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis